肺纤维化的新型吸入疗法:原则,应用和前景
Meiling Zheng1,2, Wei Zhu3, Fei Gao4
1Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, 100010, China.
新型吸入疗法在治疗肺纤维化 (PF) 方面表现有前途. 本综述探讨了先进的技术和药物输送方法,突出了它们克服局限性的潜力,并改善了这种不可逆转的肺部疾病的患者结果.
科学领域:
- 肺部医学 肺部医学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 肺纤维化 (PF) 是一种渐进的,不可逆转的肺部疾病,影响全球数百万人.
- 虽然PF的确切原因尚不清楚,但可以在不同阶段进行治疗干预.
- 吸入疗法对喘和COPD成功,目前正在为PF治疗探索.
研究的目的:
- 为肺纤维化的新型吸入疗法提供全面的审查.
- 分析这些治疗方法的药理学,制药学,技术,临床前和临床方面.
- 专注于增强现有技术的方法,并扩大PF的吸入药物选择.
主要方法:
- 对PF的吸入疗法的当前文献的综述.
- 微粒子和纳米粒子输送系统的分析.
- 检查基因疗法,信号通路调节器和细胞外囊泡干预措施.
- 评估影响安全性和有效性的因素,包括颗粒性质,生物障碍和设备类型.
主要成果:
- 各种新的吸入技术,包括纳米粒子,传统中医,基因疗法和细胞外囊泡,在治疗PF方面表现出有效性.
- 治疗成功取决于吸入颗粒的特性,生物障碍和吸入装置的设计.
- 该审查综合了关于PF的先进吸入策略的临床前和临床数据.
结论:
- 吸入疗法为治疗肺纤维化提供了显著的优势,尽管存在限制.
- 在吸入技术和药物开发方面进一步的研究和创新对于推进PF治疗至关重要.
- 新的方法有望改善肺纤维化患者的治疗结果.
更多相关视频
02:46A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization
Published on: January 20, 2023
07:38A Multimodal Imaging Approach Based on Micro-CT and Fluorescence Molecular Tomography for Longitudinal Assessment of Bleomycin-Induced Lung Fibrosis in Mice
Published on: April 13, 2018
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Inhaled Medications
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
